MedTrace Logo

A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer

NCT05619172 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2025-07-24

Study results available
· View outcomes & findings →

Summary

The primary objective of the study is to estimate the antitumor efficacy of nanrilkefusp alfa (SOT101) in combination with cetuximab in RAS wild-type colorectal cancer.

Conditions

Interventions

DRUG

Nanrilkefusp alfa

Subcutaneous (SC) injection

DRUG

Cetuximab

Intravenous (IV) infusion via peripheral or central venous line

Sponsors & Collaborators

  • SOTIO Biotech AG

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-22
Primary Completion
2024-03-06
Completion
2024-06-05
FDA Drug
Yes

Countries

  • Belgium
  • France
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05619172 on ClinicalTrials.gov